首页> 外文OA文献 >Polymyxin B-immobilised haemoperfusion and mortality in critically ill patients with sepsis/septic shock: A protocol for a systematic review and meta-analysis
【2h】

Polymyxin B-immobilised haemoperfusion and mortality in critically ill patients with sepsis/septic shock: A protocol for a systematic review and meta-analysis

机译:多粘菌素B固定的脓毒症/败血性休克重症患者的血液灌流和死亡率:系统评价和荟萃分析的方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction: Polymyxin-B immobilised haemoperfusion (PMX-HP) is a promising adjuvant strategy for the treatment of sepsis and septic shock. PMX-HP therapy works by clearing circulating endotoxin through binding to polymyxin-immobilised fibres during haemoperfusion. Small clinical trials have shown that PMX-HP therapy is associated with improved haemodynamic profile, oxygenation and survival. However, clear inferences have been largely inconclusive due to limitations in study design (eg, small, unblinded) and generalisability. We therefore propose to perform an up-to-date systematic review and evidence synthesis to describe the efficacy, safety and effectiveness of PMX-HP for adult patients with sepsis or septic shock. Methods and analysis: We will search the following databases from 1946 to 2016 MEDLINE (Ovid), EMBASE (Ovid), Cochrane Library, Health Technology Assessment Database (HTA), Cumulative Index to Nursing and Allied Health Literature (CINAHL), PubMed and 'Igaku Chuo Zasshi' (ICHUSHI) for randomised controlled trials of PMX-HP in critically ill patients with sepsis or septic shock. There will be no language restrictions in the electronic search for studies. Two reviewers will extract data and appraise the quality of each study independently. The primary outcome will be the pooled risk ratio of 28-day all-cause mortality. Serious adverse events and changes in organ dysfunction scores will also be evaluated. The secondary outcomes will be 90-day all-cause mortality, changes in haemodynamic profile and endotoxin levels, and health services use. Ethics and dissemination: Our systematic review will synthesise the evidence on use of the PMX-HP as an adjuvant therapy in sepsis/septic shock to improve patient-centred, physiological and health services outcomes. Research ethics is not required for this review. The study will be disseminated by peer-reviewed publication and conference presentation.
机译:简介:固定化多粘菌素B的血液灌注(PMX-HP)是用于治疗败血症和败血性休克的有希望的辅助策略。 PMX-HP治疗通过在血液灌流过程中与固定化多粘菌素的纤维结合来清除循环内毒素,从而发挥作用。小型临床试验表明,PMX-HP治疗与改善的血液动力学特征,氧合作用和存活率有关。但是,由于研究设计的局限性(例如,小盲者)和普遍性,明确的推论在很大程度上尚无定论。因此,我们建议进行最新的系统评价和证据综合,以描述PMX-HP对败血症或败血性休克成人患者的疗效,安全性和有效性。方法和分析:我们将搜索1946年至2016年的以下数据库:MEDLINE(Ovid),EMBASE(Ovid),Cochrane图书馆,健康技术评估数据库(HTA),护理和相关健康文献累积索引(CINAHL),PubMed和“ Igaku Chuo Zasshi'(ICHUSHI)用于败血症或败血性休克危重患者的PMX-HP随机对照试验。电子搜索研究将没有语言限制。两名审稿人将提取数据并独立评估每个研究的质量。主要结果将是28天全因死亡率的合并风险比。严重的不良事件和器官功能障碍评分的变化也将得到评估。次要结果是90天全因死亡率,血液动力学特征和内毒素水平的变化以及卫生服务的使用。道德与传播:我们的系统评价将综合使用PMX-HP作为败血症/败血性休克辅助治疗以改善以患者为中心,生理和卫生服务成果的证据。此审查不需要研究伦理。这项研究将通过同行评审的出版物和会议介绍进行传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号